Hypertensive patients from the RADIANCE-HTN SOLO trial who received renal denervation sustained a lower blood pressure through six months compared to participants randomized to a sham procedure, despite being placed on fewer antihypertensive medications during follow-up.
Nicholas Conn, PhD, a postdoctoral fellow at Rochester Institute of Technology and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system (Photo credit: A. Sue Weisler/RIT).
Researchers from the Rochester Institute of Technology are leveraging “natural processes” to provide insights into heart health with a toilet seat-based cardiovascular monitoring system.
A post-FDA approval study of Abbott’s CardioMEMS heart failure sensor found the device reduced HF-related hospitalizations by 58 percent in a trial group of 1,200 patients, researchers reported at this year’s American College of Cardiology symposium in New Orleans.
A catheter ablation protocol for atrial fibrillation (AFib) including only “the bare essentials” of the procedure delivered similar outcomes as a more involved strategy featuring pulmonary vein mapping, according to research presented at EHRA 2019.
Intravascular ultrasound (IVUS)-guided PCI was associated with lower long-term risk of cardiac death than an angiography-guided approach in patients with complex lesions, according to a single-center study published in JACC: Cardiovascular Interventions.
A remote monitoring protocol for heart failure patients with implantable electronic devices helped more of them stay out of the hospital over a one-year period than standard in-person visits, researchers reported at EHRA 2019.
Richard Kovacs, MD, left, assumes the role of American College of Cardiology president from C. Michael Valentine, MD, on March 18 at the ACC's scientific sessions in New Orleans (Photo by Todd Buchanan/ACC).
Richard Kovacs, MD, officially began his one-year stint as the president of the American College of Cardiology on March 18. The occasion was marked during a convocation ceremony on the final day of the ACC’s scientific sessions in New Orleans.
NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light.
NEW ORLEANS — An antithrombotic regimen of apixaban plus a P2Y12 inhibitor such as clopidogrel lowered bleeding events and hospitalizations compared to warfarin plus clopidogrel in a cohort of patients with atrial fibrillation (AFib) and a recent acute coronary syndrome (ACS), according to results of the AUGUSTUS trial.
NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.
